This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Long-term rivastigmine treatment in a routine clinical setting


Minthon, L., Wallin, A. K., Eriksson, S., Wattmo, C., Andreasen, N.


Acta Neurologica Scandinavica, Volume: 119, No.: 3, Pages.: 180-185

Year of Publication



Objective: The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer’s disease (AD) in a routine clinical setting.; Methods: This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician’s Interview-Based Impression of Change (CIBIC) and the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog).; Results: Of 217 patients initiated into rivastigmine treatment, 62% (n = 135) remained on treatment for 24 months. Most patients droped out due to nursing home placement or side effects. Eighty per cent and 67% of completers exhibited a symptomatic attenuation of cognitive decline (< or = 4-point deterioration) as assessed by using the MMSE and ADAS-cog respectively. Forty-four per cent showed an unchanged/improved CIBIC rating.; Conclusions: Over 60% of patients remained on treatment for 2 years in this routine clinical setting. In patients who remained on treatment, rivastigmine appeared to stabilize their condition and prevented or delayed symptomatic decline.;

Bibtex Citation

@article{Minthon_2009, doi = {10.1111/j.1600-0404.2008.01086.x}, url = {}, year = 2009, month = {mar}, publisher = {Wiley-Blackwell}, volume = {119}, number = {3}, pages = {180--185}, author = {L. Minthon and {AA}. K. Wallin and S. Eriksson and C. Wattmo and N. Andreasen}, title = {Long-term rivastigmine treatment in a routine clinical setting}, journal = {Acta Neurologica Scandinavica} }


activities of daily living, administration & dosage, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, drug therapy, female, humans, male, middle aged, neuropsychological tests, nootropic agents, phenylcarbamates, prospective studies, rivastigmine, severity of illness index, sweden, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime